Urology Center of Englewood
Latest Clinical News

Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (07-12-2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing... Continue Reading

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (06-7-2017)

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months... Continue Reading

Avelumab Immunotherapy Approved for Bladder Cancer (05-15-2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy... Continue Reading

FDA Approves Imfinzi for Treatment of Urothelial Cancer (05-11-2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing... Continue Reading

Unique Gene Signature Predicts Potentially Lethal Prostate Cancers (02-23-2017)

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of... Continue Reading

FDA Approves Opdivo for Treatment of Bladder Cancer (02-16-2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (10-3-2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10... Continue Reading

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer (08-15-2016)

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently published in the Journal of Clinical Oncology. Prostate... Continue Reading

New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer (08-10-2016)

Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have treatment options: active surveillance, also called... Continue Reading

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (07-26-2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (06-13-2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second... Continue Reading

Tecentriq® Approved for Bladder Cancer (06-8-2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Next Page »